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Abstract 
 Genetic engineering has always held great opportunity for the field of gene 
therapy. If the cause of a genetic disease can be determined, correction of this gene would 
allow for an efficient and permanent cure. However, current technologies utilizing 
engineered retroviruses have serious drawbacks that significantly limit their practical 
applications for gene therapy. 
 In this project we investigate a novel genetic editing technology called TALENs. 
By utilizing a modular protein isolated from a plant pathogen that can be quickly and 
efficiently redesigned to recognize and bind to any desired sequence of DNA combined 
with a nuclease, we can target a double stranded break at any location in the genome, 
setting off a cascade of events we can exploit to insert a new sequence of DNA at the site 
of the double stranded break
1
.   
 While the goal is to develop the TALENs technology for use on humans, 
extensive research is needed before human trials can be conducted. Our group is testing 
this in the model organism C. elegans, a soil nematode used for genetic studies. One 
advantage of doing this is the ability to microinject fluid into the gonad of a young adult 
worm, which will be absorbed by forming oocytes (eggs) during development. Thus any 
genetic change will be permanent in the subsequent generations. This fluid will contain 
two important components: mRNA that will code of the TALENs protein to create the 
double stranded break at the desired location, and a DNA segment that contains 
homology, or matching base pairs on both sides of the double stranded break, allowing 
the cell to repair itself with the provided template. We will be tagging our particular gene 
of interest, lin-39, with GFP to visualize its expression while simultaneously 
demonstrating the ability to utilize TALENs technology to insert a full gene into the 
genome.  
 We have successfully created the mRNA and template components to inject into 
C. elegans. Continued work on this project will produce a useful GFP fusion protein for 
the Miller lab and will also demonstrate a viable genetic engineering technology that will 
eventually facilitate gene therapy.   
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List of Abbreviations 
 CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats): Specific 
DNA sequences found on a specific area on the chromosome that contain 
multiple, short, direct repetitions of base sequences. Often associated with Cas 
genes which code for proteins. The CRISPR-Cas9 system can be used to modify 
the gene (i.e. induce double strand breaks). 
 
DNA (Deoxyribonucleic acid): The molecule that encodes the entire genetic 
structure of all living organisms; made up of four nucleotides (also referred to as 
bases) recorded as the letters G (guanine), A (adenine), T (thymine), and C 
(cytosine).  Most DNA molecules are double-stranded helices. 
 
 GFP (Green Fluorescent Protein): A protein that exhibits green fluorescence 
when exposed to ultraviolet light. 
 
HR (Homologous Recombination): A process that is highly conserved amongst 
all organisms where the cell recognizes a double-stranded break and works to 
repair itself. It seeks homology (matching DNA sequences), and uses these to 
recombine the DNA avoiding mutations. 
 
 mRNA (Messenger Ribonucleic Acid): A family of RNA molecules that 
facilitates the translation of DNA into its protein form. 
 
NHEJ (Non-Homologous End Joining): A repair mechanism used by cells to 
quickly fix double-stranded breaks; usually results in mutations. 
 
 PCR (Polymerase Chain Reaction): A biochemical technology used to amplify 
(produce millions of copies) a specific sequence of DNA 
 
 RNA (Ribonucleic Acid): A family of biological molecules that perform various 
roles in the coding, decoding, regulation, and expression of genes and is compiled 
 viii 
of the nucleotides G (guanine), A (adenine), U (uracil), and C (cytosine) and is 
usually single-stranded. 
 
RVD (Repeat Variable Diresidue): The loops of the TALEN protein that are able 
to bind to specific nucleotides (bases) of DNA. 
 
SCID (Severe Combined Immunodeficiency): A genetic disease that results in the 
complete compromise of one’s immune system; can be caused by a single point 
mutation. 
 
 TALENs (Transcription Activator-Like Effector Nucleases): A protein that 
consists of a binding domain (made up of a custom array of RVDs) and a nuclease 
that is able to induce a double strand break in DNA. 
 
UTR (Untranslated Region): The section of DNA that immediately follows the 
stop codon of the translation coding region. 
 
 ZFN (Zinc Finger Nuclease): Consists of an array of zinc finger proteins that is 
able to bind to a specific DNA sequence and a nuclease that is able to induce a 
double strand break in DNA. 
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Introduction and Significance 
Background/Motivation 
One of the many promises of genetic engineering is the potential it holds for gene 
therapy. Genetic engineering gives us the ability to correct errors in the genome, 
altering or adding a new function gene that the one lacks. Current technologies (to 
be discussed in the following section) exist in gene therapy that allow scientists to 
insert new healthy genes. However, these have significant drawbacks that have 
kept them from becoming viable treatment options.   
 
Our overarching goal is to utilize a novel technology called Transcription 
Activator-Like Effector Nucleases (TALENs) to create a tool that researchers will 
be able to use to insert a healthy gene at the endogenous (native) location on the 
genome. This gene insertion will be done utilizing a fluorescent protein known as 
GFP (green fluorescent protein). Upon successful insertion GFP into our gene of 
interest, our method may be applied for the development of gene therapy. 
 
Critique of Current Technologies 
There are several technologies that have spearheaded the movement in genetic 
engineering, especially gene therapy. These technologies that exist have been 
clinically applied to fix a disease that is caused by a genetic mutation. The first 
attempt at gene therapy was using retroviral vectors to insert a healthy gene into 
the genome in order to fix an unhealthy gene
2
. A retroviral vector is able to insert 
into the genome the same way a virus does, except instead of adding viral DNA, 
they could add new synthetic healthy genes designed by researchers. So once the 
modified retroviral vector is inserted into the genome, it would effectively “cure” 
the patient.  
 
Retroviral vectors were used on those who suffered from severe combined 
immunodeficiency (SCID), which results in the complete comprise of one’s 
immune system
2
. This can be caused by a single mutation in the genome and has 
drastic effects on one’s quality of life. There are several genes that, when 
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defective, can result in a dysfunctional immune system – those children who have 
a mutation in one of the X-linked genes are often referred to as having “bubble 
boy” syndrome, because those who suffer from SCID often have to avoid 
exposure to germs by living in a protective, sterile “bubble”. In 2003, Scientists 
were able to use retroviral vectors to infect and insert the healthy gene into the 
SCID patients’ genomes2.  
 
Viruses are used as vehicles to deliver DNA to a cell. The virus first finds a way 
to invade the cells, then is able to inject its own DNA to overtake the cell’s 
environment to make it more favorable for itself. By using this mechanism, 
scientists are able to engineer these viruses so instead of injecting their own DNA, 
they will inject a healthy version of the gene causing some genetic disease. 
Retroviruses are particularly useful for gene therapy because their viral life cycle 
results in the integration of the viral genome into the host genome. If the virus can 
be “tricked” into inserting a good copy of the gene that needs to be “fixed”, the 
hope was that this would result in a permanent correction of the mutation. When 
inserted into the genome, the DNA brought in by the retrovirus has now become a 
permanent part of the patient’s genome, in essence, a cure. In 2003, scientists 
attempted this with one of the SCID genes on the X chromosome. By engineering 
a retroviral vector to insert a healthy version of the gene causing SCID, 9 of the 
10 children who received retroviral gene therapy started to develop a functional 
immune system
2
.  
 
The drawback of this approach, however, is that the site of viral insertion into the 
genome cannot be controlled. If the healthy gene is integrated too close to an 
oncogene, it can activate the oncogene, which can lead to the development of 
cancer. Although a functioning immune system was restored in all 10 patients, 2 
of them later developed leukemia to integration close to an oncogene
2
. The viral 
vectors are able to infect human cells at high efficiency and restore function 
permanently, but the potential side effects posed by random integration create too 
high of a risk to be a truly viable solution.  
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In order to combat the uncontrollable integration of a healthy gene into the 
genome, scientists need a way to target a specific place in the DNA to insert a 
gene so it would not be close to an oncogene and consequently turn it on. The best 
possible location for the new healthy gene is the exact location on the genome that 
it would exist naturally. In order to create site-specific gene integration, we can 
utilize a double-stranded break in the DNA.  
 
Creating a double-stranded break is important for site-specific integration. When 
a double-stranded break is created in the DNA, the cell will work quickly to repair 
itself through one of the two highly conserved processes: either non-homologous 
end joining (NHEJ) or homologous recombination (HR) (Figure 1). NHEJ is an 
imperfect process that usually results in mutations, so ideally HR would be 
preferred. Homologous Recombination is utilized in situations where, for 
instance, there exists a piece of donor DNA that matches both the left and the 
right side of where the double stranded break occurs, so that piece of DNA will be 
utilized as a repair template, thus avoiding random mutations and uncontrollable 
integration. 
 
 
Figure 1: Nuclease-Induced Genome Editing
4
. An induced double-stranded break can be repaired 
by either non-homologous end joining (NHEJ; thin arrow line) or by homology-directed repair 
(HDR; thick black line). HDR is also known as homologous recombination (HR). The NHEJ 
repair mechanism is imperfect, as it can often lead to mutations caused by insertions or deletions. 
Homologous recombination is utilized when a donor DNA template exists to cause precise 
insertion where a double-stranded break exists.  
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However, the problem is not that scientists don’t know how to create a double-
stranded break in DNA; the problem is creating a double strand break at a single 
targeted (specific) site. Restriction enzymes have been used for years to create 
double strand breaks, but they are not specific enough and would result in 
multiple breaks within the genome. So if, for example, a well-known enzyme 
such as EcoRI, which on average every 4,000 base pairs, was used to create 
double-stranded breaks in the 3 billion base-pair human genome, it would create 
far too many fragments (about 750,000) for the cell to repair effectively and the 
genome would be destroyed. 
 
To avoid uncontrolled integration, a new approach was developed to create 
double-stranded breaks at targeted sites in the genome. The first of these 
technologies that was developed to create a double-stranded break at a specific 
site was Zinc-Finger Nucleases (ZFNs). Scientists were able to utilize the DNA-
binding motif of Zinc-Finger Proteins with a restriction enzyme called FokI to 
create a site-specific double stranded break. The zinc-finger protein is able to 
recognize a specific DNA sequence and FokI is able cleave target DNA
13
. While 
these proteins work as expected, they are difficult and expensive to create. It is a 
viable approach, but it was not effective enough to take hold in the industry. 
 
 
Figure 2: Visual of Zinc Finger Nucleases
13
. Each zinc finger protein is able to bind to 3 base 
pairs (indicated by vertical arrows). Specific arrangement of multiple zinc finger proteins is able to 
direct ZFNs to a specific DNA sequence. Fok1 nuclease induces a double-stranded break.  
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Another new technology is the CRISPR/Cas9 approach. Cas9 is a protein that 
binds and cleaves DNA. The CRISPR/Cas9 system utilizes a guide RNA to target 
the correct DNA sequence, and then is able to create a double-stranded break
3
. 
While this approach has been used, it is still being developed. At this time, it also 
requires the permanent addition of CRISPR/Cas9 DNA into cells in order to 
create the double stranded break. Since this addition is undesirable for gene 
therapy applications, we decided to move forward using TALENS as our 
technology platform of choice.   
 
 
Figure 3: Visual of CRISPR/Cas9
3
. Guide RNA is used to direct Cas9 protein to induce a double 
stranded break at targeted DNA.  
 
Review of Current Technology 
TALENs are a protein derived from a plant pathogen, Xanthomomas, that is able 
to infect a host plant, making the host’s environment more favorable to the 
bacteria
5
. This protein affects gene transcription, in a similar manner to native 
transcription-activators (control the gene transcription of DNA into a protein), 
leading to the name of Transcription Activator-Like Effector, or TALEs.  
 
Upon analysis of this protein structure, scientists saw that it consisted of a highly 
repetitive structure
6
. These repetitions consist of protein loops of 33 amino acids 
that are almost all identical. Out of the identical amino acids of each protein loop, 
the only variation is seen in two adjacent amino acids. These varying 2 amino 
acids are responsible for recognizing a specific nucleotide of DNA (either A, C, 
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G, or T); that is, there is one specific loop that is able to recognize one specific 
nucleotide. While this mechanism is quite similar to the DNA binding property of 
ZFNs, the repeating loops make the customization much easier. Instead of 
designing a whole new Zinc-Finger, one would simply have to put the repeating 
loops in an order that corresponded to the desired DNA sequence to bind. Once 
the amino acid loops have been customized to a specific DNA sequence and is 
combined with the FokI endonuclease, Transcription Activator-Like Effector  
Nucleases (TALENs) hold the power to create targeted double-strand breaks in 
DNA, but with a modularity that makes their customization fast and easy.  
 
 Statement of Project Goal 
The main goal of our project is to demonstrate the ability to utilize this novel 
TALENs technology to insert a GFP fusion gene in the genome. To do this, we 
are using the model organism C. elegans, a soil nematode commonly used to 
study genetics. As the Miller Lab studies vulval development, we utilized the 
gene insertion to corroborate ongoing research in the lab. Our target gene will be 
lin-39, which is turned on in specific cells during vulval development
11
.  
 
Utilizing TALENs, our goal is to insert the DNA coding for a lin:39::GFP fusion 
gene into the endogenous lin-39 gene location. Green Fluorescent Protein (GFP) 
is a fluorescent protein isolated from glowing jellyfish. This will enable us to 
visualize when lin-39 is turned on endogenously (in its normal chromosomal 
environment) by visualizing green fluorescence. We accomplish this in three main 
steps: 
 
1. Building of two TALENs DNA constructs to direct a double-strand break 
within the lin-39 gene. 
2. Construction of lin-39::GFP temple.  
3. Creation of microinjection mix consisting of the TALENs mRNA 
transcribed from the TALENs DNA created in step 1, and the GFP DNA 
template created in step 2 
 7 
Steps 1 and 2 are done in parallel and step 3 can be accomplished after successful 
completion of the prior two steps. 
 
By inserting GFP directly after the lin-39 gene, we are creating a protein fusion 
that allows expression of GFP with lin-39. Whenever lin-39 is expressed, GFP 
will be attached to it and will fluoresce. It is important to note that the fusion of 
lin-39 to GFP has been performed before. However, this has been done 
extrachromosomally
12
. Because the fusion gene is not integrated at the lin-39 
endogenous location, it may not replicate the true nature of how and when lin-39 
is regulated because chromosomal location can affect gene expression, a 
phenomenon known as position effect
13
.  So by tagging lin-39 endogenously with 
GFP, we are able to monitor the true expression. 
 
While this process is executed in C. elegans, the process is robust, and can be 
applied to any type of organism, including humans. Thus, this project 
demonstrates the ability to insert a full gene, or repair an existing gene at the exact 
site that the gene exists naturally. Once this has been established, TALENs has 
the potential to be developed for gene therapy applications. 
 
Significance 
Successful insertion of the GFP gene in a tiny nematode does not prove that the 
TALENs technology is ready for human trials or experiments. It does, however, 
provide a very large and significant step in demonstrating the principle and 
efficacy to use TALENs for genetic engineering and perhaps even gene therapy. 
TALENs provide a way to integrate a gene exactly where intended, and doesn’t 
require the permanent addition of foreign DNA that is undesirable. While there is 
still a long road to travel, our project with TALENs demonstrates a clear path 
towards viable therapeutic genetic engineering.  
 
 
 
 8 
Budget 
Item Name Vendor Catalog # Cost 
TALENs 
 DNA 
Golden Gate TALEN and 
TAL Effector Kit 2.0 
Addgene 1000000024 $425 
mRNA 
Assembly 
mMessage mMachine 
SP6 Transcription Kit 
Ambion AM1340 $428 
mRNA 
Purification 
Megaclear Kit Ambion AM1908M $110 
Restriction 
Enzymes 
BsaI, BsmBI, Acc65I 
New England 
Biolabs 
R3535S, R0580S, 
R0599S 
$194 
TOTAL    $1,157 
 
Timeline 
September 21 – December 13    Preliminary research; planning and assignment of 
execution of specific steps of project 
January 1 – March 21               Completion of Step 1 (design and construction of 
TALENs DNA) and Step 2 (construction of 
donor DNA) 
March 31 – May 8                      Microinjection and screening of progeny for 
expression of GFP; Presentation at Senior Design 
Conference hosted by School of Engineering 
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1. TALENs Design & Construction 
 Introduction 
In order to target a double strand break in the DNA at a specific site, the TALENs 
protein must be able to bind to a specific sequence. To bind to a specific 
sequence, we must construct a sequence of DNA that will code for a sequence of 
amino acids which will construct the TAL effector domain. The TAL effector 
domain is responsible for the site-specific targeting in the DNA and the Fok1 
nuclease attached to this domain induces a double-stranded break. 
 
The structure of TALENs allows us to build a customizable protein that is able to 
target any sequence. The DNA-binding motif is constructed of identical repeating 
loops that are able to wrap around the DNA and bind to a specific sequence. 
These loops are made up of 33-34 amino acids that are all exactly the same, 
except the 12
th
 and 13
th
 amino acids. These two amino acids that vary are 
responsible for binding to a specific base pair (either A, C, G, or T). These 
specific loops that bind to a single nucleotide are called a repeat variable 
diresidues (RVDs). So by changing the order of these repeating loops, we are able 
to effectively bind to any sequence targeted in the genome. 
 
 Key Constraints 
As we create the TALE vector, there are key constraints we must consider upon 
design and creation. First, we must consider where we want the double strand 
break to occur. Our goal is to insert GFP closest to the end of the coding region of 
lin-39 near the 3’ untranslated region (UTR). Because the TALE must bind to a 
specific sequence within lin-39, the RVDs that bind to a specific nucleotide must 
be constructed in a specific order. That is, if given a sequence CCATTG, then we 
must design a TALE consisting of RVD(C) - RVD(C) - RVD(A) - RVD(T) - 
RVD(T) - RVD(G). (RVD(C) denotes the specific RVD that bind to C.) These 
specific RVDs that bind to a specific base pair are given a two letter abbreviation, 
based on the varying 12
th
 and 13
th
 amino acids. HD, NG, NI, and NH correspond 
to one of the four bases, C, T, A, and G, respectively. 
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 Design Overview 
The construction and design of a TALEN takes minimum 5 days as outlined by 
the Voytas lab
1
. Using an online tool provided by Cornell University, we are able 
to input the region of DNA where we would like the double strand break to occur 
and the program will output various TAL effector designs
1
. We have chosen to 
create a double strand break just before the stop codon of lin-39 (Figure 4). Our 
RVD sequence for our TALEN is as follows: 
 
TALEN 1: HD NH NH NG HD HD NI NG NG HD HD NH NH NG NG HD HD HD NI HD 
TALEN 2: NI NG NI NI NI NI NG NH NH HD NI NH NG NI NI HD NG 
 
 
 
 
 
 
Figure 4. Design of TALENs protein to target end of lin-39. The Fok1 nucleases will create a 
double-stranded break at the 3’ end of the coding region of lin-39 (blue region) near the 
untranslatable region (UTR). 
 
TALEN1 has a total of 20 RVDs while TALEN2 has a total of 18 RVDs. Using 
this order of RVDs, we are able to go forth with the first part of constructing the 
TALENs DNA. Using the Golden Gate TALEN and TAL Effector Kit 2.0, we 
were able to perform the first of two Golden Gate reactions. The first Golden Gate 
reactions are performed to build an array of the first 10 RVDs of TALEN1, an 
array of 9 consisting of RVDs 11-19 of TALEN1, an array of first 10 RVDs of 
TALEN2, and an array of 7 consisting of RVDs 11-17 of TALEN2. A total of 4 
Golden Gate reactions were performed. 
 
After the first Golden Gate reactions were successfully constructed and 
transformed, we proceeded with the second round of Golden Gate reactions. This 
reaction joined the two separate arrays (i.e. RVDs 1-10 of TALEN1 will join with 
RVDs 11-19 of TALEN1) into a backbone vector along with the final RVD of 
lin-39 
TALEN 1 TALEN 2 
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each TALEN (i.e. RVD 20 for TAL1 and RVD 18 for TAL2). A control was 
performed by performing the second Golden Gate reaction with the backbone 
vector that was included in the Golden Gate kit. However, this TALENs DNA 
was not able to be injected into C. elegans.  
 
After successful construction of the TALENs DNA using all components of the 
Golden Gate kit, the second round of Golden Gate reactions was performed using 
a backbone optimized for use in C. elegans. The backbone was provided to us by 
the Ellis lab. Upon completion of these second Golden Gate reactions, the 
TALENs constructs were ready to use and inject in to C. elegans. 
 
 Supported Analyses 
After each Golden Gate reaction was created, we performed a polymerase chain 
reaction (PCR) and ran the product on a 1.0% agarose gel to confirm that our 
array contained the correct amount of RVDs. We expected to see an array with 10 
RVDs to run at around 1.2 kb and 100-200 bp less for every RVD. Further 
analysis was done by sequencing to confirm the correct order of RVDs in a 
selected array. Final sequencing of the TALENs was performed to confirm 
successful insertion of RVDs in the backbone (see Appendix A). 
 
 Expected Results 
We expected to be able to create two TALENs that would be able to induce a 
double strand break at our directed site in lin-39. This procedure had never been 
done in the Miller Lab before so extra precautions were taken, however all of the 
procedures were similar to standard molecular biology protocols. 
 
 Materials & Methods 
All materials and methods are outlined in the Golden Gate TALENS Kit 2.0 
provided by Addgene and the Voyatas lab
1
. Instead of using the backbone vector 
in which the TALENs DNA would be inserted, we inserted the TALENs DNA 
into a backbone optimized for C. elegans provided by the Ellis lab.  
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Results 
The first array, containing the first 10 RVDs and last 9 RVDs of TALEN 1 and 
the first 10 RVDs and last 7 RVDs of TALEN 2 were successfully ligated 
together in the first Golden Gate reaction. We picked 3 white colonies (blue/white 
selection) from the transformed and performed PCR amplification on each of the 
plasmids to confirm the correct length of each array. The arrays that were of the 
right length were sequenced to confirm the correct order of the RVDs.  
 
Figure 5: Agarose gel of first Golden Gate reactions. 1 kb ladder is used in Lane 1. Lane 2 is the 
first 10 RVDs of TALEN1, Lane 3 is the first 10 RVDs of TALEN2, Lane 4 is the RVDs 11-19 of 
TALEN1, and Lane 5 is the RVDs 11-17 of TALEN2. Correct bands appear for all reactions; 
lanes 1 and 2 are around 1.2 kb with lanes 3 and 4 slightly less due to fewer RVDs ligated during 
Golden Gate reactions. Bands around 3kb are other products from PCR reaction, however, since 
bands appear around 1kb, we know that successful first Golden Gate reactions occurred. 
 
Ligation of the first array, second array, and final RVD together into the backbone 
vector was performed in the second round of Golden Gate reactions. We picked 3 
white colonies from these transformed second Golden Gate reactions. Sequencing 
was performed to confirm successful ligation and construction of the TALENs 
DNA.  
 
 
 
 
 3 kb   
 
 
1.0 kb  
1     2     3    4     5 
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Discussion 
We were successfully able to construct the TALENs DNA that will code for the 
TALENs protein to create a double-stranded break at the end of the lin-39 coding 
region. By performing the control where the entire construction was performed 
using all provided vectors in the Golden Gate kit, we were able to successfully 
show that we are able to perform the construction of the TALENs DNA. 
 
After successfully proving that we are able to construct the TALENs DNA using 
all vectors provided in the Golden Gate kit, we then performed the second Golden 
Gate reactions with vectors not provided in the kit. The two arrays from the first 
Golden Gate reactions were used, as well as the last RVD, provided in the Golden 
Gate kit, however, we ligated the separate arrays in a backbone vector donated to 
the Miller Lab. This backbone vector was optimized for use in C. elegans.  
 
New primers were designed to optimize sequencing for new backbone; we did not 
visualize the gel on an agarose gel. Successful ligation of these arrays was 
confirmed by commercial sequencing (see Appendix A).  The TALENs DNA was 
then used to transcribe the TALENs mRNA as well for the injection mix into C. 
elegans. 
  
 14 
2. Donor DNA Construction 
 Introduction 
In order to introduce a new gene into the C. elegans genome, we must provide a 
template for the genome to repair itself once the double-stranded break is created 
with the TALENs protein. The template matches the genomic DNA on the left 
and right of the GFP gene. Thus, when the cell seeks to repair itself, the template 
provided by the synthetic vector allows the introduction of GFP and the creation 
of a lin-39::GFP protein fusion.  
 
 
 
  
 
 
 
Figure 6. Insertion of GFP by Homologous Recombination. (A) Targeted double-stranded break 
at the end of the coding region of lin-39 will allow for insertion of donor DNA (B) containing 
GFP utilizing homologous recombination. (C) Final product will be the fusion of lin:39::GFP at 
the endogenous site. 
 
 Key Constraints 
As we create the GFP vector, we must be mindful of several key constraints. The 
first is that we have enough homology on both sides of the introduced GFP. This 
ensures that the new DNA will be able to properly anneal to the existing genomic 
DNA. The second is that the GFP gene we insert is “in frame” with the existing 
lin-39 gene. Since amino acids are created from 3 base-pair coding sequences 
called codons, it is imperative that the GFP codons match exactly to the lin-39 
codons. The final constraint is the verification of this construct. If an incorrect 
construct is injected into the animals, the experiment will fail.  
 
  
 
A. 
B. 
C. 
 15 
Design Overview 
This genetic construct is synthesized in three steps. The first step is to extract the 
native genomic lin-39. The second step is to subclone the first fragment (coding 
region) into a GFP vector. The third step is to subclone the second fragment (3’ 
UTR) into the same vector. The final product will be the coding region of lin-39, 
followed by the coding region of GFP, and finally the 3’ UTR of lin-39.  
 
 Supported Analyses 
Each step described above is verified prior to the continuation onto the next step. 
The first step will be easy to verify by running the PCR product on an agarose gel. 
If the reaction proceeds as expected, a single dark band of 2kb will be visible on 
the gel. The second step and third steps will also be verified by length on an 
agarose gel. These will take more careful scrutiny, as a difference in size of 4.5kb 
and 5kb, and subsequently 5kb and 5.8kb, will need to be selected. Finally, 
commercial sequencing will be conducted to support our agarose gel data. 
 
 Expected Results 
Our group expects to be able to fully synthesize and verify this construct, as it is 
necessary for the microinjections of the C. elegans. The general procedures are 
quite common in the Miller lab, but extra precautions to ensure the validity of our 
construct will be absolutely necessary.  
 
 Materials & Methods 
In order to successfully synthesize the repair template of DNA, we must first 
obtain genomic lin:39 DNA and the DNA sequence immediately following it. By 
designing primers recognizing the edges of the target region, we can utilize a 
procedure called “Worm PCR” to obtain this DNA. The worm cells are lysed, 
allowing collection of the worm genome. This genome is then used as a template 
for PCR, which will copy the DNA as directed by the designed primers
7
.  
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The second step is to subclone the end of lin-39 into a GFP vector. To accomplish 
this, primers are designed to replicate only the first half of the previous segment 
of DNA. These primers also included “linkers” which are extra segments of DNA 
that do not match the exact template. However, these will be added as the DNA is 
copied, allowing us to add sites for restriction enzymes that we used to insert the 
DNA into the GFP vector
9
. 
 
The third step is very similar to the last, but this time the second half of the 
original genomic DNA will be replicated. Once again, restriction sites were added 
using “linker primers” that allowed the DNA segment to be subcloned into the 
GFP vector
9
. The final product can be seen below, as the DNA sequence 
contained the end of lin-39, followed by GFP, and then ending with the genomic 
DNA that immediately follows lin-39. 
 
 Results 
Our group has successfully been able to synthesize the repair DNA template. 
There are four important steps to verify this process. The first is to demonstrate 
that we have successfully synthesized and isolated the genomic lin-39 DNA using 
PCR. An agarose gel is used to confirm the proper length of DNA, seen below. 
 
 
Figure 7: Agarose gel of genomic lin-39. Correct band length around 3kb indicates successful 
synthesis and isolation of lin-39. 1kb ladder used.  
 lin-39 
1kb 
ladder 
3 kb  
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Using this repair template, the first half of the DNA containing the end of lin-39 
was replicated once again via PCR and added onto the front of the GFP gene. This 
was verified by using the same restriction enzymes that were used to insert the 
DNA initially. By redigesting and running a gel, we can visualize an insert of the 
proper length has indeed been added. We are also able to verify the second insert 
(containing the DNA directly following lin-39) in this same manner. 
 
  
Figure 8: Digest analysis of plasmids confirms successful insert. Left: plasmids digested with 
HindIII & Acc65I show a band around 1kb, representing the lin-39 homology. Right: plasmids 
digested with EcoRI show a band around 800bp, representing the insert containing the homology 
directly following lin-39. 
 
However, we used a single restriction enzyme (EcoRI) to digest the second insert. 
This means that it could be in one of two directions. We can screen for a correctly 
oriented insert using PCR. We designed primers that will only allow the DNA to 
replicate if the insert is facing the correct direction. By visualizing this PCR 
produce we are able to ensure the insert is facing the correct direction. 
 
Figure 9: Agarose gel of PCR products. A strong band indicates the PCR was successful, meaning 
the insert is in the correct orientation. 
 
 
100bp 
ladder 
1kb 
ladder 
1kb   
insert  
800 bp 
insert     
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Once we had a vector that had passed through all three steps, we utilized 
commercial sequencing to verify the DNA construct (see Appendix B), which 
demonstrated the correct DNA sequence for the repair template.  
 
 Discussion 
All of our results have led to the correctly synthesized DNA repair template. 
While commercial sequencing was necessary to verify our DNA sequence, the 
intermediate checkpoints ensured that we would generate our expected sequence.  
 
This DNA repair template provides a DNA vector with homology on both sides of 
the targeted double-stranded break. Once the cell seeks to repair itself, it will use 
our DNA repair template, and will integrate the GFP gene with it.  
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3. Microinjection & Screening 
 Introduction 
To introduce the TALENs protein and template construct, a combination of 
mRNA and DNA is introduced into the gonads of C. elegans animals. The C. 
elegans oocytes are part of a syncytium in the gonad, without cell walls. Thus, by 
simply microinjecting a solution containing the TALENs mRNA and DNA 
construct, when the cell wall are formed around the oocytes, they will envelop the 
mRNA and DNA with it. The mRNA will be translated into mature TALENs 
protein, and will induce a targeted double-stranded break in the genome. Once 
this happens, the cell will seek a template to repair itself, which has already been 
provided in the form of the DNA construct. Once this injection has been 
completed, the next generation of animals will be screened for fluorescence when 
lin-39 is expected to be activated.  
 
 Details of Key Constraints 
The key feature of TALENs that makes it so promising amongst the current 
genetic engineering technologies is the fact that no extra genetic material is left 
after the completion of the genetic editing. mRNA is difficult to synthesize and 
manipulate because it degrades easily. However, this also means that any leftover 
mRNA will not remain in the cell permanently, ensuring that no excess genetic 
material is leftover in the host genome. The DNA template, once it has been used 
by the cell to repair itself, will be destroyed as well.  
 
Design Overview 
This process has been well established and utilized in the C. elegans community 
to introduce new genes into the genome. However, it usually entails injecting 
DNA by itself. This DNA is incorporated into the genome as an 
extrachromosomal array. However, it is impossible to identify exactly how the 
DNA has been incorporated. It can have many copies of the same gene, or none at 
all. Especially when studying promoters and transcription factors, the location and 
relative number is critical. By instead utilizing TALENs to create a double 
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stranded break and incorporate endogenously, we are able to mitigate these issues 
and gain a clearer picture of the behavior of lin-39. 
 
 Supported Analyses 
We will have several checkpoints to validate our procedures. Since mRNA is so 
easily degraded, we will pay special attention to the in vitro transcription reaction. 
To show that the mRNA has not been degraded, it must be run on an agarose gel. 
If the mRNA is intact, a single bright band will emerge on the gel. If the mRNA 
has been exposed to RNase, it will appear as a smear or there will not be enough 
left to visualize on a gel. 
 
Utilizing this technique, we will visualize the mRNA at two times during the 
process. The first is immediately following the transcription reaction to verify that 
the reaction worked as expected. After this the mRNA will be purified and frozen 
in aliquots. Once again we will verify that the mRNA is still intact by thawing an 
aliquot and running it on a gel. By doing this, we will be able to verify that the 
mRNA is intact at the time of injection.  
 
Finally, we will prove the ability of our lab to successfully introduce the TALENs 
proteins into live animals. To do this we will use a TALENs protein that has been 
provided to us from the Ellis lab (see acknowledgments) that is known to target 
the dpy-5 gene. When injected into the C. elegans gonad, this TALENs protein 
will create a double-stranded break within the dpy-5 gene that, when repaire by 
non-homologous end joining, will result sometimes in a mis-repair. This mis-
repair will create mutation within the dpy-5 gene that will give the animals a 
Dumpy (short and fat) phenotype. This will be easier to screen than the 
fluorescence in the vulva. Through this we will validate the ability to create 
mutations by microinjection of mRNA.  
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 Expected Results 
Our lab has been able to successfully microinject DNA in C. elegans, so we 
expect to be able to do so with mRNA as well. It will take extra precautions to 
ensure the mRNA is still viable, as well as extra scrutiny during the screening 
process to observe the fluorescence. If the microinjection goes as planned, we will 
be able to observe fluorescence in the vulval precursor cells during vulval 
development.  
 
 Materials & Methods 
The mRNA was transcribed using the mMessage mMaschine SP6 Kit. This kit 
allows for in vitro transcription of a linear DNA segment. Thus the DNA was 
digested with the restriction enzyme HindIII, and purified using a 
phenol/chloroform extraction. The mRNA was then created using the protocol 
provided with the kit
8
. After this, it was purified and brought up to higher 
concentration using the MEGAclear Kit according to the protocol provided
7
. 
Once this mRNA was created, it was combined with the DNA repair template and 
microinjected into the gonads of the animals.  
 
Results 
 The transcription of the mRNA can be visualized below: 
 
Figure 10: mRNA transcript on agarose gel. Transcript runs at 3kb as expected and absence of 
smearing indicates absence of RNase activity 
 
 
 3kb 
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The presence of a single band at the proper length, without smearing indicates that 
the mRNA has not been exposed to RNase. Thus the mRNA is intact and has not 
been degraded. This means that it is ready to be combined with the DNA and 
injected. 
 
Microinjections have been performed, however, no successful integration has 
been discovered at this time. No GFP-positive vulval precursor cells have been 
screened. 
 
 Discussion 
At this time, we have been unable to demonstrate the successful integration of the 
GFP gene. It could be due to two possible causes: the TALENs protein is not 
cutting the DNA, or the DNA repair template is not being used to insert the GFP 
gene. In order to combat the first issue, higher concentrations of mRNA are used 
to yield more protein and thus, yield a proportionally higher level of double-
stranded breaks. This, in turn, will yield integration of the GFP gene if our 
hypothesis is correct. Until we can verify that our DNA is being cut by the 
TALENs protein, increasing the concentration of the DNA repair template will 
not help, as increases the likelihood that the DNA will integrate 
extrachromosomally in the absence of a double stranded break. Moving forward, 
we are confident that more trials will demonstrate this process, as the TALENs 
cut is a relatively low frequency event. However, a single cut and integration will 
demonstrate the possibilities of this protocol, and will allow research to move 
forward. Although this targeted gene integration has not yet been demonstrated, 
TALENs still holds serious potential as a genetic engineering technology.  
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Summary & Conclusion 
Overall, we have been able to successfully create the TALENs DNA, the mRNA from the 
TALENs DNA, the donor DNA to be inserted at the site of the double-stranded break, 
and have performed microinjections. The TALENs DNA was designed and constructed 
to target the end of the coding region of lin-39 so that when the double strand break is 
created by the TALENs protein, the donor DNA, which has homology to the left side and 
the right side of the double-stranded break, will insert into the genome through 
homologous recombination. The TALENs mRNA was successfully transcribed in vitro, 
noted by the lack of smearing on the agarose gel that would indicate degradation.  We 
will continue to microinject the mix of TALENs mRNA, TALENs DNA, and the donor 
DNA into C. elegans and monitor the progeny of these worms for the expression of GFP. 
 
Further work must be done to show that it is possible to insert genes into the endogenous 
site of an organism’s DNA. Even though we are not able to conclude a potential new 
method that can be used as a tool for genetic engineering until we are able to monitor 
expression of GFP, we have successfully established a new protocol to be utilized in the 
Miller Lab.  
 
However, should future work to be done to show successful expression of GFP in C. 
elegans, we have potentially established a new method of genetic engineering that may 
be applicable to gene therapy. We are able to avoid the uncontrollable integration of a 
healthy gene into the genome by retroviruses by utilizing the TALENs protein to create a 
site-specific double-stranded break where our donor DNA will be able to insert using 
homologous recombination for seamless integration.  
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Appendix A 
The desired sequence of RVDs for the TALENs to create a double stranded break at the 
end of lin-39 is as follows: 
TALEN1: HD NH NH NG HD HD NI NG NG HD HD NH NH NG NG HD HD HD NI HD 
TALEN2: NI NG NI NI NI NI NG NH NH HD NI NI NH NG NI NI HD NG 
 
As stated in “1. Design and Construction of TALENs”, we have sequenced the TALENs 
DNA. Below are the sequencing results: 
 
 
(1) The first array of RVDs 1-10 for TALEN 1, forward sequencing. Variations of blue 
correspond to HD, red corresponds to NH, gold corresponds to NG, and pink corresponds 
to NI. First 8 of 10 RVDs successfully sequenced forward giving RVD sequence of HD 
NH NH NG HD HD NI NG. 
 
 
(2) The first array of RVDs 1-10 for TALEN 1, reverse sequencing. Same color code as 
used in (1). Sequence is in reverse and shows RVDs 10-4 with sequence HD NG NG NI 
HD HD NG. Combined forward and reverse sequence files of TALENs 1 shows 
successful ligation of the first array of 1-10 RVDs. 
 
 
(3) The second array of RVDs 11-19 for TALEN 1, forward sequencing. Same color code 
as used in (1). RVDs 11 – 17 successfully sequenced forward: HD NH NH NG NG HD 
HD.  
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(4) Second array of RVDs 11-19 for TALEN 1, reverse sequencing. Same color code as 
used in (1). Successful reverse sequence of RVDs 19-13: NI HD HD HD NG NG NH. 
Results of (3) combined with (4) indicate successful creation of the second array of 
TALEN 1 of RVDs 11-19 to later be combined with RVDs 1-10 and RVD 20. 
 
 
(5) First array of RVDs 1-10 for TALEN 2, forward sequencing. Same color code as used 
in (1). Forward sequencing successful of RVDs 1-7 producing RVD sequence of NI NG 
NI NI NI NI NG.  
 
  
(6) First array of RVDs 1-10 for TALEN 2, reverse sequencing. Same color code as used 
in (1). Reverse sequence of first 10 RVDs show sequence of RVDs 10-4 with sequence as 
follows: HD NH NH NG NI NI NI. Results of (5) and (6) show successful creation of 
first array of TALEN 2 RVDs 1-10. 
 
 
(7) Second array of RVDs 11-17 for TALEN 2, forward sequencing. Same color code as 
used in (1). Successful forward sequencing of second array for TALEN2: NI NI NH NG 
NI NI HD. Second array is now ready to be ligated with RVDs 1-10 and RVD 18 of 
TALEN2. Reverse sequence of second array not shown as forward sequence was able to 
show entire array sequence. 
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(8) Complete TALEN 1, forward sequencing. Same color code as used in (1). Forward 
sequence of TALEN 1 shows RVDs 1-7 of TALEN 1: HD NHNH NG HD HD NI. 
 
 
(9) Complete TALEN 1, reverse sequencing. Same color code as used in (1). Reverse 
sequence of TALEN 1 shows RVDs 20-15: NH NI HD HD HD NG. Sequencing is not 
available for entire TALENs DNA, as it is too long to be sequenced entirely. Since 
forward sequencing was able to show correct beginning sequence of RVDs and reverse 
sequencing was able to show correct ending sequence of RVDs, we can conclude that 
TALEN 1 was successfully created. 
 
  
(10) Complete TALEN 2, forward sequencing. Same color code as used in (1). Forward 
sequence of TALEN 2 shows RVDs 1-8: NI NG NI NI NI NG NH. 
 
(11) Complete TALEN 2, reverse sequencing.  Same color code as used in (1), however 
last RVD NG is purple instead of its usual color code of gold. Reverse sequence of 
TALEN 2 shows RVDs 18-12: NG HD NI NI NG NH NI. Since forward and reverse 
sequencing show both correct beginning and ending RVDs, respectively, then we can 
assume that TALEN 2 was successfully created. 
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Appendix B 
 
 
 
Repair fragment sequencing. Comparison of the commercial sequencing file to expected 
repair fragment sequence yields a perfect match to both the fragment sequence and the 
vector, indicating the repair fragment has been inserted in the correct alignment.  
 
